Search
Zotiraciclib
go.drugbank.com/drugs/DB16656InvestigationalZotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide
FT-1101
go.drugbank.com/drugs/DB17553Investigational[A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Triglyme
go.drugbank.com/drugs/DB02078ExperimentalTriethylene glycol dimethyl ether (also called triglyme) is a glycol ether used as a solvent.
Categories: Compounds used in a research, industrial, or household settingTriethylene glycol
go.drugbank.com/drugs/DB02327ExperimentalCategories: Compounds used in a research, industrial, or household settingCyclomethicone
go.drugbank.com/drugs/DB14124InvestigationalCategories: Compounds used in a research, industrial, or household setting4-(4-fluoro-phenylazo)-5-imino-5H-pyrazol-3-ylamine
go.drugbank.com/drugs/DB08667ExperimentalThese are compounds containing one or more fluorine atoms attached to a benzene ring. This substance targets the protein methionine aminopeptidase.
SR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
Tosatoxumab
go.drugbank.com/drugs/DB16557InvestigationalTosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Navocaftor
go.drugbank.com/drugs/DB19039InvestigationalNavocaftor is under investigation in clinical trial NCT04853368 (Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/navocaftor/abbv-119 or Galicaftor/navocaftor